Inhibikase Therapeutics (IKT) Change in Cash (2020 - 2026)

Inhibikase Therapeutics (IKT) has reported Change in Cash for 7 consecutive years, with -$89.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Cash fell 628.86% year-over-year to -$89.6 million; the TTM figure through Mar 2026 stood at -$23.9 million (down 133.58% YoY), while the FY2025 annual figure was $82.7 million, up 74.81% from the prior year.
• Change in Cash fell to -$89.6 million in Q1 2026 per IKT's latest filing, from $101.0 million in the prior quarter.
• Across five years, Change in Cash topped out at $101.0 million in Q4 2025 and bottomed at -$89.6 million in Q1 2026.
• Historically, Change in Cash has averaged $519022.2 across 5 years, with a median of -$2.2 million in 2024.
• Annual changes were most pronounced in 2024 — Change in Cash surged 1075.7% — and 2025, when it slumped 1716.49%.
• Inhibikase Therapeutics' Change in Cash stood at $1.4 million in 2022, then slumped by 504.95% to -$5.7 million in 2023, then soared by 1075.7% to $55.6 million in 2024, then jumped by 81.64% to $101.0 million in 2025, then plunged by 188.8% to -$89.6 million in 2026.
• Business Quant data shows IKT's Change in Cash at -$89.6 million in Q1 2026, $101.0 million in Q4 2025, and -$39.5 million in Q3 2025.